Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.44 USD | -1.53% | -8.26% | -13.98% |
May. 09 | UBS Adjusts Price Target on REGENXBIO to $39 From $43, Maintains Buy Rating | MT |
May. 08 | Transcript : REGENXBIO Inc., Q1 2024 Earnings Call, May 08, 2024 |
Business Summary
Number of employees: 344
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Gene Therapy
100.0
%
| 113 | 100.0 % | 90 | 100.0 % | -19.94% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
International
68.0
%
| 62 | 55.0 % | 61 | 68.0 % | -1.02% |
United States
32.0
%
| 39 | 35.0 % | 29 | 32.0 % | -26.81% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Kenneth Mills
FOU | Founder | 49 | 08-07-15 |
Vit Vasista
DFI | Director of Finance/CFO | 56 | 09-07-31 |
Chief Tech/Sci/R&D Officer | - | 15-10-31 | |
Olivier Danos
CTO | Chief Tech/Sci/R&D Officer | 66 | 17-03-27 |
Stephen Pakola
CTO | Chief Tech/Sci/R&D Officer | 55 | 19-04-16 |
Curran Simpson
COO | Chief Operating Officer | 62 | 15-07-31 |
Shiva G. Fritsch
IRO | Public Communications Contact | - | 16-12-31 |
Laura Coruzzi
PRN | Corporate Officer/Principal | 71 | - |
Ram Palanki
PRN | Corporate Officer/Principal | 48 | 18-07-31 |
General Counsel | 53 | 16-07-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
George Migausky
BRD | Director/Board Member | 69 | 21-09-02 |
David Stump
BRD | Director/Board Member | 74 | 15-10-14 |
Director/Board Member | 71 | 15-04-30 | |
Daniel Tassé
BRD | Director/Board Member | 64 | 16-08-14 |
Director/Board Member | 65 | 18-05-24 | |
Allan Fox
CHM | Chairman | 76 | 08-12-31 |
Kenneth Mills
FOU | Founder | 49 | 08-07-15 |
Jennifer Zachary
BRD | Director/Board Member | 46 | 22-06-02 |
Jean Bennett
BRD | Director/Board Member | 69 | 21-02-28 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 49,255,966 | 45,393,655 ( 92.16 %) | 0 | 92.16 % |
Company contact information
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.98% | 761M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- RGNX Stock
- Company REGENXBIO Inc.